Omid C. Farokhzad

Omid Farokhzad is a Professor at Harvard Medical School and Brigham and Women's Hospital. He is one of the world's leading translational nanomedicine researchers and entrepreneurs, known for developing targeted polymeric nanoparticle platforms that have advanced to human clinical trials. Working closely with Robert Langer, he developed PLGA-PEG nanoparticles functionalized with cancer-targeting aptamers — a platform that became the basis for BIND-014, the first targeted nanoparticle to enter Phase II clinical trials for cancer treatment. He co-founded multiple companies including BIND Biosciences (NASDAQ) and Selecta Biosciences. His laboratory focuses on engineering nanoparticles that can navigate biological barriers, reach tumor targets, and deliver drugs with unprecedented precision, overcoming the limitations of standard chemotherapy.

Omid Farokhzad 是哈佛医学院和布莱根妇女医院的教授。他是世界领先的转化纳米医学研究者和企业家，以开发进入人类临床试验的靶向聚合物纳米颗粒平台而闻名。 与Robert Langer密切合作，他开发了用癌症靶向适配体功能化的PLGA-PEG纳米颗粒——这一平台成为BIND-014的基础，即第一个进入II期癌症治疗临床试验的靶向纳米颗粒。他共同创立了多家公司，包括BIND Biosciences（纳斯达克上市）和Selecta Biosciences。